A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects

Trial Profile

A Phase 1, Randomized, Double-blind, Placebo-controlled, Ascending Single Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AMG 529 in Healthy Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2017

At a glance

  • Drugs AMG 529 (Primary) ; AMG 529 (Primary)
  • Indications Cardiovascular disorders
  • Focus Adverse reactions; First in man
  • Sponsors Amgen
  • Most Recent Events

    • 28 Sep 2017 Planned End Date changed from 3 Nov 2017 to 6 Nov 2017.
    • 28 Sep 2017 Planned primary completion date changed from 3 Nov 2017 to 6 Nov 2017.
    • 28 Sep 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top